BRAF and melanoma: The potent B-raf inhibitor PLX4720 (PLX) that acts against melanoma reduced the binding of C-MYC to the VEGF promoter to reduce the expression of VEGF in melanoma cells and increased the infiltration of adoptively transferred T cells, thereby leading to an antitumor effect [10].